This announcement is a separate document:
JCRファーマ：ムコ多糖症IIIB型に対するJR-446の第I/II相試験の治験計画届受理および治験計画に関する当局調査終了について
JCR Pharmaceuticals: Acceptance of the investigational plan for Phase I/II trials of JR-446 for Mucopolysaccharidosis IIIB and completion of regulatory authority investigation regarding the clinical trial plan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.